

**Anti-TNFSF5 / CD40L / CD154 Reference Antibody (letolizumab)  
Recombinant Antibody  
Catalog # APR10637**

**Specification**

---

**Anti-TNFSF5 / CD40L / CD154 Reference Antibody (letolizumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P29965</a>
Reactivity	Cynomolgus, Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	39 KDa

**Anti-TNFSF5 / CD40L / CD154 Reference Antibody (letolizumab) - Additional Information**

**Target/Specificity**  
TNFSF5 / CD40L / CD154

**Endotoxin**  
< 0.001EU/ µg, determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

**Anti-TNFSF5 / CD40L / CD154 Reference Antibody (letolizumab) - Protein Information**

**Name** CD40LG

**Synonyms** CD40L, TNFSF5, TRAP

**Function**  
Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed: [1280226](http://www.uniprot.org/citations/1280226), PubMed: [31331973](http://www.uniprot.org/citations/31331973)). Costimulates T-cell proliferation and cytokine production (PubMed: [8617933](http://www.uniprot.org/citations/8617933)). Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in

conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:<a href="http://www.uniprot.org/citations/8617933" target="\_blank">8617933</a>). Induces the activation of NF-kappa-B (PubMed:<a href="http://www.uniprot.org/citations/15067037" target="\_blank">15067037</a>, PubMed:<a href="http://www.uniprot.org/citations/31331973" target="\_blank">31331973</a>). Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:<a href="http://www.uniprot.org/citations/15067037" target="\_blank">15067037</a>). Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:<a href="http://www.uniprot.org/citations/15067037" target="\_blank">15067037</a>). Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity).

#### Cellular Location

Cell membrane; Single-pass type II membrane protein. Cell surface

#### Tissue Location


Specifically expressed on activated CD4+ T- lymphocytes

### Anti-TNFSF5 / CD40L / CD154 Reference Antibody (Ietolizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-TNFSF5 / CD40L / CD154 Reference Antibody (Ietolizumab) - Images



Anti-TNFSF5 / CD40L / CD154 Reference Antibody (Ietolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF5 / CD40L / CD154 Reference Antibody (letolizumab) is more than 98.32% ,determined by SEC-HPLC.